OVERVIEW

The management of hyperphosphatemia, secondary hyperparathyroidism and vitamin D deficiency are challenging conditions to manage in dialysis patients. These conditions are also highly prevalent in later-stage CKD-ND patients. Current therapeutic options have multiple limitations and are associated with poor adherence. The introduction of the first IV calcimimetic has shifted the landscape and new pipeline treatments for phosphate binders, along with an update to the KDIGO guidelines for CKD-MBD will likely contribute to future change in treatment patterns.

This report series, published bi-annually in the EU5 (UK, Germany, France, Spain and Italy) focuses on tracking key performance metrics for phosphate binders, calcimimetics and active vitamin D agents in both the dialysis and CKD-ND settings. Emphasis is placed on identifying the opportunity for pipeline agents.

SAMPLE & METHODOLOGY

~250 nephrologists from the UK, Germany, France, Spain and Italy will complete an online survey. Participants must meet certain screening criteria. Quotas are established to capture a regionally and demographically representative sample.

KEY QUESTIONS ANSWERED

- What shifts are occurring in CKD-MBD in the dialysis setting and do these changes vary by country? Are these expected to change in the next six months and if so, why?
- How do treatment rates and approaches for phosphate binders, active vitamin D and calcimimetics and in what ways do these differ between dialysis and CKD-ND patients?
- What are the utilization trends between Mimpara and Parsabiv? What are the perceived differences between these agents?
- What are nephrologists views on the use of calcium-based binders and to extent is the update to KDIGO’s Clinical Practice Guidelines for CKD-MBD influencing use?
- How do nephrologists perceive the dual effect of ferric citrate with its impact on both phosphorus and anemia parameters?
- How does the unmet need for new phosphate binders compare to the unmet need in other areas of nephrology?
- What does the promotional landscape look like for the overall nephrology market and how do CKD-MBD products measure up? Which manufacturers are perceived as being the strongest partners in CKD-MBD management?
- Who are the leading CKD-MBD experts in Europe?